Affinity Asset Advisors, LLC
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$1.76B2026 Q3+ $694.7M options (notional, not included)
Positions121
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.41.5%
What Changed This Quarter?
Top Holdings
IWMPUT
Ishares Tr
11.3%
ROIV
Roivant Sciences
4.8%
SYRE
Spyre Therapeutics
4.6%
XBIPUT
SPDR Series
3.9%
ERAS
Erasca
3.3%
TRAX
First Tracks Biotherapeutics
3.0%
XENE
Xenon Pharmaceuticals
2.9%
INSM
Insmed
2.6%
New / Increased
33 new · 30 increased
IWMPUTNEW
Ishares Tr
11.3%
XBIPUTNEW
SPDR Series
3.8%
ARKGPUTNEW
Ark ETF Tr
2.2%
IBRXPUTNEW
Immunitybio
1.7%
SMMTPUTNEW
Summit Therapeutics
1.2%
ARWR
Arrowhead Pharmaceuticals In
1.1%
+183.3%
ALKS
Alkermes
2.6%
+39.1%
CLDX
Celldex Therapeutics
1.5%
+65.8%
Reduced / Exited
28 reduced · 25 sold out
MRNACALL
Moderna
2.0%
-47.4%
ANAB
Anaptysbio
0.1%
-92.0%
MRNAPUT
Moderna
2.5%
-35.0%
ROIV
Roivant Sciences
4.8%
-14.7%
ELVN
Enliven Therapeutics
0.3%
-70.4%
Apogee Therap…EXIT
Apogee Therapeutics
5.9%
NUVLEUREXIT
Nuvalent
1.5%
FBRXGBPEXIT
Forte Biosciences
1.1%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.